W4

Synthetic lignans targeting cardiovascular diseases

Prof. Marko Mihovilovic, Technical University Vienna;  Dr Thomas Linder, Technical University Vienna;  Prof. Verena M. Dirsch, University of Vienna;  Dr David Bernhard, University of Innsbruck;  Prof. Hermann Stuppner, University of Innsbruck

Austria Wirtschaftsservice


Challenge

Within a joint research approach researchers at Vienna University of Technology, University of Innsbruck, Vienna University and Medical University of Vienna have identified novel synthetic lignans to affect inflammatory processes related to surgical cardiovascular intervention.


Technology

Novel synthetic lignans to affect inflammatory processes related to surgical cardiovascular intervention have been identified. Starting from natural compound leoligin, improved synthetic analogs were prepared with favourable properties to prevent VSMC proliferation concomitantly not affecting EC to keep blood vessel structural integrity unaffected.

The novel compounds may have highly beneficial effects for preparation of cardiac by-pass implants as well as for stent conduits. Potential applications range from administration within by-pass preparation to controlled-release devices for stents.


Commercial Opportunity

Collaboration, License, Purchase


Development Status

Lead optimization


Patent Situation

Priority 2014
AT, EP, US patents filed


Further Reading

WO2015196228 A1


 

Synthetic lignans targeting cardiovascular diseases
Synthetic lignans targeting cardiovascular diseases

Starting from natural compound leoligin, improved synthetic analogs were prepared